KalVista Pharmaceuticals Raises $33M in Series B Financing

KalVista Pharmaceuticals, a UK-based pharmaceutical company, has raised $33 million in Series B funding. The round was led by Novo A/S, SV Life Sciences, RA Capital Management, Longwood Fund, and Venrock. The company intends to use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).

KalVista Pharmaceuticals Secures $33 Million in Series B Funding

KalVista Pharmaceuticals is a Porton Down, UK-based research-led pharmaceutical company focused on developing and patenting a diverse pipeline of selective and potent plasma kallikrein inhibitors designed for different routes of administration. The company's most advanced program, an intravitreally administered plasma kallikrein inhibitor, has just completed its first-in-human study and will move into Phase 2 trials in 2016 for the treatment of diabetic macular edema (DME). KalVista also has an office in Boston, MA, USA.

A research-led pharmaceutical company focused on developing and patenting a diverse pipeline of selective and potent plasma kallikrein inhibitors for the treatment of diabetic macular edema (DME) and hereditary angioedema (HAE).

10 years ago

KalVista Pharmaceuticals Secures $33 Million in Series B Funding

ProblemFinancial Services

Solution

Covered on